# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
Goldman Sachs analyst Nathan Rich maintains Amneal Pharmaceuticals (NASDAQ:AMRX) with a Buy and raises the price target from...
Truist Securities analyst Les Sulewski reiterates Amneal Pharmaceuticals (NASDAQ:AMRX) with a Buy and raises the price targe...
Amneal Pharmaceuticals settles $270 million opioid crisis agreement, offering cash and naloxone spray. Boosted by strong Q1 ear...
Amneal Pharmaceuticals (NYSE:AMRX) reported quarterly earnings of $0.14 per share which beat the analyst consensus estimate of ...
Novel 505(b)(2) presentation of a key injectable for treating non-squamous non-small cell lung cancer and malignant pleural mes...
Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) along with its gastroenterology business, Salix Pharmaceuticals, Inc., announc...